11/24
09:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/7
06:19 am
abvx
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/5
07:02 pm
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
11/4
07:21 am
abvx
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/3
04:05 pm
abvx
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
Low
Report
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
10/13
07:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $142.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) was given a new $142.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/10
07:19 am
abvx
Abivax (NASDAQ:ABVX) was given a new $150.00 price target on by analysts at Guggenheim.
Low
Report
Abivax (NASDAQ:ABVX) was given a new $150.00 price target on by analysts at Guggenheim.
10/6
05:02 pm
abvx
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Low
Report
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research.
10/6
04:00 am
abvx
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Low
Report
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
10/5
11:00 am
abvx
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Medium
Report
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
10/3
02:37 pm
abvx
Abivax (NASDAQ:ABVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Abivax (NASDAQ:ABVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/29
04:05 pm
abvx
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Low
Report
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
9/25
10:17 am
abvx
Abivax (NASDAQ:ABVX) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
9/25
09:07 am
abvx
Abivax (NASDAQ:ABVX) had its price target raised by analysts at JMP Securities from $95.00 to $114.00. They now have a "market outperform" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) had its price target raised by analysts at JMP Securities from $95.00 to $114.00. They now have a "market outperform" rating on the stock.
9/23
04:05 pm
abvx
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Low
Report
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
9/13
01:07 am
abvx
Low
Report
9/12
11:49 am
abvx
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Morgan Stanley from $71.00 to $101.00. They now have an "overweight" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Morgan Stanley from $71.00 to $101.00. They now have an "overweight" rating on the stock.
9/12
11:45 am
abvx
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Low
Report
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
9/9
08:07 am
abvx
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $112.00 price target on the stock.
Low
Report
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $112.00 price target on the stock.
9/8
04:00 pm
abvx
Abivax Presents First Half 2025 Financial Results
Low
Report
Abivax Presents First Half 2025 Financial Results